Shareholders might have noticed that Middle East Healthcare Company (TADAWUL:4009) filed its quarterly result this time last week. The early response was not positive, with shares down 5.3% to ر.س34.98 in the past week. Middle East Healthcare reported in line with analyst predictions, delivering revenues of ر.س765m and statutory earnings per share of ر.س3.28, suggesting the business is executing well and in line with its plan. This is an important time for investors, as they can track a company's performance in its report, look at what expert is forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analyst is expecting for next year.

Following the latest results, Middle East Healthcare's sole analyst are now forecasting revenues of ر.س3.42b in 2026. This would be a notable 9.0% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to shrink 9.3% to ر.س1.65 in the same period. In the lead-up to this report, the analyst had been modelling revenues of ر.س3.46b and earnings per share (EPS) of ر.س1.90 in 2026. So there's definitely been a decline in sentiment after the latest results, noting the real cut to new EPS forecasts.

It might be a surprise to learn that the consensus price target was broadly unchanged at ر.س66.30, with the analyst clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Middle East Healthcare's past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of Middle East Healthcare'shistorical trends, as the 12% annualised revenue growth to the end of 2026 is roughly in line with the 13% annual growth over the past five years. Juxtapose this against our data, which suggests that other companies (with analyst coverage) in the industry are forecast to see their revenues grow 11% per year. It's clear that while Middle East Healthcare's revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.

The Bottom Line

The biggest concern is that the analyst reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Middle East Healthcare. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have analyst estimates for Middle East Healthcare going out as far as 2028, and you can see them free on our platform here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.